Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(2006): Andersen KE+, Contact Dermatitis 55(6), 354 (oleyl
alcohol)
Edema
(2006): Richter B+, Cochrane Database Syst Rev (4), CD006060
Herpes simplex (1.2%)
Molluscum contagiosum (1.2%)
Peripheral edema
(2006): Boden G+, Expert Opin Investig Drugs 15(3), 243
(2006): Johansen OE+, Tidsskr Nor Laegeforen 126(15), 1928
(2006): Majima T+, Endocr J 53(3), 325
Rosacea
(2006): El Sayed F+, JAmAcadDermatol54(3), 548
(2006): Hughes PS, JAmAcadDermatol54(3), 546
Tinea
(2004): Crawford KM+, Skinmed 3(6), 352
Eyes
Macular edema
(2006): Ryan EH Jr+, Retina 26(5), 562
Other
Application-site burning (8–26%)
Application-site irritation (0.9%)
(2003): Allen BR+, Arch Dis Child 88(11), 969 (5 cases)
Application-site pruritus (0.6%)
Application-site reactions (sic) (2.1%)
Cough
(2002): Wahn U+, Pediatrics 110(1 Pt 1), e2
Infections (5.4%)
(2002): Wahn U+, Pediatrics 110(1 Pt 1), e2 (12.4%)
Upper respiratory infection (19.4%)
PIMOZIDE
Trade names: Frenal; Neurap; Orap (Gate); Pimodac
Indications: Tourette’s syndrome, schizophrenia
Category: Antipsychotic
Half-life: 50 hours
Clinically important, potentially hazardous interactions
with: amphetamines, aprepitant, atazanavir, azithromycin, azole
antifungals, clarithromycin, darunavir, dirithromycin,
erythromycin, fluoxetine, fosamprenavir, grapefruit juice,
imatinib, indinavir, itraconazole, ketoconazole, methylphenidate,
nefazodone, nelfinavir, pemoline, phenothiazines, protease
inhibitors, quinidine, ritonavir, saquinavir, sertraline, sparfloxacin,
telithromycin, thioridazine, tipranavir, tricyclic antidepressants,
troleandomycin, voriconazole, zileuton, ziprasidone
Reactions
Skin
Diaphoresis
Exanthems
Facial edema (1–10%)
Photosensitivity
(1991): Opler LA+, J Clin Psychiatry 52, 221
Pigmentation
(1991): Opler LA+, J Clin Psychiatry 52, 221
Pruritus
Rash (sic) (8.3%)
Urticaria
Mucosal
Sialorrhea (13.8%)
(1987): Shapiro AK+, Pediatrics 79, 1032
Xerostomia (>10%)
(1991): Opler LA+, J Clin Psychiatry 52, 221
(1990): Sandor P+, J Clin Psychopharmacol 10, 197
(1987): Shapiro AK+, Pediatrics 79, 1032
Eyes
Periorbital edema
Other
Death
(2001): Glassman AH+, Am J Psychiatry 158(11), 1774
Gynecomastia (>10%)
Myalgia/Myositis/Myopathy/Myotoxicity (2.7%)
PINDOLOL
Trade names: Alti-Pindolol; Apo-Pindol; Barbloc; Durapindol;
Gen-Pindolol; Nonspi; Pinbetol; Pinden; Syn-Pindol; Visken
(Novartis); Vypen
Indications: Hypertension
Category: Adrenergic beta-receptor antagonist
Half-life: 3–4 hours
Clinically important, potentially hazardous interactions
with: clonidine, epinephrine, verapamil
Note: Cutaneous side effects of beta-receptor blockaders are
clinically polymorphous. They apparently appear after several months
of continuous therapy. Atypical psoriasiform, lichen planus-like, and
eczematous chronic rashes are mainly observed. (1983): Hödl St, Z
Hautkr (German) 1:58, 17
Reactions
PINDOLOL 441
Skin
Diaphoresis (2%)
Eczema
Edema (6%)
Erythema multiforme
Exanthems
Exfoliative dermatitis
Hyperkeratosis (palms and soles)
Lichenoid eruption
Lupus erythematosus
Peripheral edema
Pityriasis rubra pilaris
Pruritus (1–5%)
Psoriasis
(1986): Abel EA+, JAmAcadDermatol15, 1007
(1986): Czernielewski J+, Lancet 1, 808
(1984): Arntzen N+, Acta Derm Venereol (Stockh) 64, 346
Purpura
Rash (sic) (1–10%)
Raynaud’s phenomenon
(1984): Eliasson K+, Acta Med Scand 215, 333
Toxic epidermal necrolysis
Urticaria
Xerosis
Mucosal
Oral lichenoid eruption
Hair
Hair – alopecia
Nails
Nails – dystrophy
Nails – onycholysis